Toxicogenomics: an emerging discipline. by Schmidt, Charles W
T
oxicology has come a long way
since Paracelsus, a scientist dur-
ing the late Middle Ages, first uttered
the phrase “the dose makes the poison.”
With these words, Paracelsus
unveiled the experimen-
tal basis of toxicology,
a science that has
recently attained a
level of sophistica-
tion that early sci-
entists could have
hardly imagined. 
Thanks to rapid ad-
vances in technology, scien-
tists are now exploring the complex
circuitry of genes and proteins that mod-
ulate toxic responses. Until recently, the
genes that make up these circuits could
be studied only in limited numbers. But
new genomic tools are making it possi-
ble to study how chemicals affect the
expression of thousands of genes either
simultaneously or sequentially along
regulatory pathways.
The resulting gene
expression patterns, or
profiles—in addition
to the cellular net-
works they give rise
to—are the hall-
marks of toxicogen-
omics. This emerging
discipline provides new
biomarkers of exposure and
effects, as well as fresh opportuni-
ties for preventing environmentally
related diseases. “Toxicogenomics opens
countless doors to our understanding
of how cells and organisms respond
to  chemical agents,” says Leona
Samson, a professor of toxicology at 
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“We’re  seeing totally unexpected cellular
processes that turn out to be toxicologically
meaningful. There’s so much to learn in terms
of how it all fits together.” 
A Basis in Genomics
As the name implies, toxicogenomics has its
roots in genomics, the study of gene function.
Among the greatest genomic achievements is
the nearly complete decoding of the human
genome. With this achievement, scientists are
describing the ordered sequence of genes in
human DNA. In recent years, the DNA of
many other organisms has also been
sequenced, providing scientists with species-
specific blueprints to the molecular machinery
of life. But as any expert will acknowledge,
gene sequences are only the master template
for this machinery; in and of themselves, they
provide little information about the way living
systems function. To understand how genomes
govern living processes, scientists must study
the biochemical networks they generate.
Scientists engaged in toxicogenomic stud-
ies apply genomic tools to learn how these net-
works modulate a cell’s response to drug or
chemical exposures. Microarrays, for example,
identify changes in gene expression associated
with specific types of toxic responses.
Proteomics—a field with many implications
beyond toxicogenomics—characterizes the
milieu of proteins appearing in a cell after a
given exposure. And with metabolomics, sci-
entists look at broad patterns of chemical
metabolites in exposed tissues. The gene, pro-
tein, and metabolite profiles that make up tox-
icogenomic data each reflect key steps leading
from exposure to disease.
By comparing chemically altered genomic
profiles to those obtained from nontreated
controls, scientists can identify unique bio-
markers for disease processes. To illustrate,
consider microarray data showing that a chem-
ical activates the genes coding for cytochrome
P450, a metabolic enzyme found in liver cells.
If the chemical also causes liver damage, scien-
tists might hypothesize that activated P450 is
involved in the toxic response mechanism. The
gene expression profile for activated P450 is
therefore a potential biomarker for chemically
induced injury to the liver. Confirming it as
such would require additional study. But even
in the absence of more complete mechanistic
data, putative toxicogenomic biomarkers can
be useful diagnostic tools for predicting toxic-
ity, says William Pennie, director of molecular
and investigative toxicology at Pfizer in
Groton, Connecticut. 
“It’s like guilt by association,” he explains.
“In isolation, you may not know how each
biomarker relates to the disease process. But
over time you might find that some are consis-
tently associated with certain toxic end points.
Then the biomarkers become increasingly pre-
dictive for these end points.” According to
Pennie, pharmaceutical and biotechnology
companies are exploring how toxicogenomic
biomarkers can be applied during new product
development. Specifically, preclinical screening
models will look for biomarkers to guide the
development of safer drugs and chemicals, he
says. Biomarkers that reliably predict certain
toxic effects may preclude the need for addi-
tional testing, he adds. Therefore, toxicoge-
nomic tools have the potential to reduce the
number of animals used in research. 
Currently, DNA-based microarrays, or
“gene chips,” so dominate the field that toxi-
cogenomics is sometimes viewed erroneously
as being concerned solely with gene expres-
sion. “This mainly reflects the advanced state
of DNA-based microarray technology,” says
Kenneth Ramos, a professor of toxicology at
Texas A&M University and the editor of EHP
Toxicogenomics Edition,a   new quarterly edi-
tion of EHP debuting in 2003. Microarrays
have emerged as widely available high-
throughput tools capable of producing global
arrays that identify all the genes expressed in a
given sample. But few, if any, laboratories have
the ability to assess all the proteins in a bio-
logical sample—although new proteomic
tools, including surface-enhanced laser des-
orption/ionization–time of flight mass spec-
troscopy and protein arrays, should facilitate
this capability within a few years.
In fact, it is likely that the most effective
diagnostic biomarkers will be proteins, says
Cynthia Afshari, associate director of toxicolo-
gy at Amgen in Thousand Oaks, California,
and former codirector of the NIEHS
Microarray Center. This is in part because pro-
teins are more stable and easier to collect in a
clinical setting than the RNA samples used to
elucidate gene expression, she says.
Furthermore, expression profiles sometimes
will not reflect important functional states that
arise from protein changes in the cell.
Over time, proteomics and metabolomics
data will become increasingly valuable for toxi-
cogenomic research, experts say. Ramos says
the NIEHS’s National Center for Toxicogen-
omics (NCT), which was established in
December 2000 to combine toxicogenomic
information with the knowledge emerging
from classical toxicology, has embraced these
technologies readily. “To achieve the goal of a
fully integrated view of toxic responses, we
need all this information,” he says. Indeed, by
combining all the toxicogenomic biomarkers,
scientists will construct the intricate biochemi-
cal pathways of toxicity.
An even clearer picture of the human
response will emerge from linking toxicoge-
nomic investigations to studies of interindivid-
ual variation. Scientists are now cataloging the
gene variants that increase or decrease human
susceptibility to chemically induced diseases.
Among these variants are simple DNA
sequence variations called single nucleotide
polymorphisms (SNPs). SNPs can influence
toxic responses in a number of ways. For
instance, a SNP might inhibit the formation of
an enzyme involved in chemical detoxifica-
tion. Individuals with such a SNP are therefore
more vulnerable to chemicals that the enzyme
would normally render harmless. 
But integrating SNP data with toxicoge-
nomics is a long way off, says NCT deputy
director James Selkirk. “When the SNPs are
identified in known genes, we can look to see
how they affect specific genomic pathways,”
he says. But many of the SNPs identified thus
far are present in genes for which the function
is still unknown.
Enhancement through Microarrays
Experts generally agree that microarrays
enabled the rise of toxicogenomics in the late
1990s. Michael Waters, assistant director for
database development at the NCT, calls
microarrays “the pivotal technology.” 
Microarrays are silicon or glass chips coat-
ed with thousands of discrete spots of nucleic
acids called probes. Each probe corresponds to
a specific gene. To use the technology, RNA
from a biological sample is “reverse tran-
scribed,” or used to produce an identical copy
of the gene that would normally be produced
in a living cell. This complementary DNA, or
cDNA, is labeled with a radioactive or fluores-
cent tag and bound to the chip. Ideally, each
molecule in the labeled cDNA binds (or
“hybridizes”) to its complementary probe on
the array. Using quantitative imaging tech-
niques that read the radioactivity or fluores-
cence, scientists assess cDNA hybridization
and thereby identify the genes expressed in the
original biological sample and their relative
levels of expression. 
In  toxicogenomic studies, the cDNA is
obtained from drug- or chemical-exposed ani-
mal tissues or cells in culture. At first, the
microarrays used in these studies were small
and contained genes for specific pathways such
as chemical metabolism or DNA repair,
Afshari says. These early microarrays and sub-
sequent refinements have enabled scientists to
pursue hypothesis-driven studies focused
mainly on obtaining additional information
about a particular toxicity mechanism.
As microarrays evolved, the number of
genes that could be placed on a chip grew rap-
idly. Today, investigators can buy chips contain-
ing tens of thousands of genes or even whole
genomes for certain species. The Santa Clara,
California–based firm Affymetrix produces sev-
eral chips that represent the entire mouse
genome. According to Waters, the availability of
these larger “discovery” chips has allowed scien-
tists to focus more broadly on gene function
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and the identification of novel pathways.
Scientists who use the larger chips are able to
find entirely new gene expression patterns and
associated mechanisms resulting from toxic
exposures. “Discovery studies are very impor-
tant, because we want to develop a more global
understanding of toxic mechanisms, and the
discovery mode allows us to do that more com-
pletely and accurately,” Waters says. 
Gene Expression and Toxicity
Carl Barrett, scientific director of the Center for
Cancer Research at the National Cancer
Institute, says the ultimate goal of toxicoge-
nomics is to link chemically induced gene
expression patterns to either detrimental, harm-
less, or even protective effects. “One should not
assume the patterns are linked to the cause of
toxicity,” he cautions. “The patterns could be
associated with responses that aren’t even toxi-
cologically relevant.” 
One way to assess the toxicological signifi-
cance of the patterns is to “phenotypically
anchor” them to standard toxicological
indices, such as clinical chemistry or tissue
pathology. Such experiments are currently a
major activity at the NCT. Phenotypic anchor-
ing, says Selkirk, is a technique that couples the
unique gene expression patterns induced by
chemical exposures to visible evidence of
harm. In this fashion, the gene expression pat-
terns provide chemical-specific signatures for
toxicological pathways and effects. 
Ideally, the signatures should relate to
expression profiles obtained at multiple dose
levels, Selkirk says. Low-dose signatures, for
example, can be correlated with small, ultra-
structural changes in cells or tissues, which are
observable only with electron microscopy.
Explains Waters, “If we can identify the gene
signatures that precede an obvious toxic out-
come, then we can use the signatures as diag-
nostic tools. Once we have an understanding
of the relationship between gene changes and
toxic effects, we can link them to reversible or
irreversible damage.” 
In what NCT director Raymond Tennant
calls “an extremely important advance for the
field,” a series of recent studies have confirmed
that gene expression patterns can provide repro-
ducible signatures for toxic mechanisms. In one
study, published in the June 2002 issue of
Toxicological Sciences, Hisham Hamadeh, previ-
ously at the NIEHS and now at Amgen, found
that compounds acting through a common
mechanism (peroxisome proliferation, a cellular
process related to oxidative stress) have similar
and collectively distinct gene expression profiles.
This means that compounds with similar mech-
anisms can be grouped by a common gene sig-
nature, which can then be used to predict the
chemical class of an unknown compound.
Linking signature profiles with toxic effects
is the goal of ongoing experiments at the NCT.
Some of these experiments are focusing on
acetaminophen, a highly studied compound
with enormous public exposure. According to
Selkirk, NCT scientists are using genomic and
proteomic tools to identify the biochemical
pathways corresponding to therapeutic and
toxic doses. “We want to study both pathways
so we know where and when they diverge, and
how toxicity is manifested,” Selkirk says. So
far, the exposures being considered in all these
studies are acute. This is mainly a function of
practicality—acute exposures produce a series
of discrete cellular events that scientists can
study to build confidence in toxicogenomic
techniques.
Unfortunately, most human exposures
aren’t so simple. People are generally exposed
to many compounds simultaneously, often on
a chronic or intermittent basis. Eventually,
Tennant says, toxicogenomics will have to
address more realistic exposure scenarios.
These pathways are much more complex, he
admits. Any evaluation of chronic exposures
must contend with the added dimensions of
time, adaptive response, and cellular repair.
“The signals for each of these processes are
masked in the complexity of the response,”
Tennant says. “With repeat dosing, it all
becomes much more intricate.” 
Knowledge and Standardization
Evaluating chronic exposures merely adds to
the already overwhelming challenge of manag-
ing toxicogenomic data. Just a few years ago,
genes involved in a given mechanism were
studied one at a time. But with the advent of
microarrays, researchers now study gene path-
ways by the hundreds, or even thousands, for
any single exposure. Add multiple doses in
varying tissues and species, not to mention
proteomic and metabolomic parameters, and
the volumes of data generated quickly over-
power most analytical capabilities. 
Data analysis and management for
genomics are the realm of the associated field
of bioinformatics, which applies computa-
tional tools toward the understanding of
biology. The goal of bioinformatics, says
Srinivasa Nagalla, director of the Center for
Biomarker Discovery at Oregon Health &
Science University, is to codify toxicogenom-
ic information in ways that facilitate “data
mining,” meaning the quick extraction of
relevant parameters stored in a database. This
capability will usher in a new era of in silico
toxicology, Nagalla says, in which scientists
use computer searching to screen biomarkers
against signature pathways. “Ultimately, for
any given tissue, you want to easily identify
expressed genes, the degree to which they are
expressed, and how those genes are linked to
each other [in pathways and networks],”
Nagalla says. “It comes down to mathemati-
cal equations for predicting gene expression
as a consequence of chemical exposure.” 
Recently, the NCT laid the groundwork
for a repository of toxicogenomic data that will
be housed at the NIEHS and made available to
scientists all over the world via the Internet.
The Chemical Effects in Biological Systems
(CEBS) database is being described as a
“knowledge base” combining toxicogenomic
biomarkers with chemical effects data.
Eventually, CEBS data sets will be searchable
by compound, structure, toxicity and patholo-
gy end point, gene, gene group, pathway, and
polymorphism, each as a function of dose,
time, species, and target tissue. Similar to the
way in which GenBank databases are queried
for genome sequences, researchers will query
CEBS to obtain information on genes and
associated toxicity pathways. If, for example,
all that is known about a newly discovered
compound is its chemical structure, scientists
could query CEBS using this information to
obtain pathway and toxicity data associated
with other, similar compounds. The CEBS
output could provide a rough screen for poten-
tial effects and new directions for future
research on the mystery compound. According
to Waters, a prototype version of CEBS, run-
ning on an Oracle database backbone, will be
online by late 2003.
But building such a database over time is
no easy task—it requires cooperation and data
sharing by researchers from many scientific
disciplines, from pathology to mathematics,
and a mutually agreeable format for linking
toxicogenomic data. According to Waters,
CEBS will soon begin accepting data from the
Toxicogenomics Research Consortium (TRC),
a group of five academic research centers, plus
the NIEHS Microarray Center, that is funded
by the NIEHS [see “Toxicogenomics Research
Consortium Sails into Uncharted Waters,”
p. A744 this issue]. Waters stresses that at some
point in the future, when minimal data stan-
dards are universally accepted, CEBS will also
accept data from many other sources, includ-
ing industry and other academic and private
research centers.
A parallel consortium to the TRC that also
aims to participate in CEBS is being coordi-
nated by the Health and Environmental
Sciences Institute of the International Life
Sciences Institute (ILSI), an independent
research organization based in Washington,
D.C. The ILSI Technical Committee on
Application of Genomics in Mechanism-Based
Risk Assessment, which includes scientists
from industry, regulatory agencies, and acade-
mia, is working on approaches to incorporate
toxicogenomic data into safety assessment for
new drugs and chemicals. Pennie, who chairs
the group, emphasizes that the generated infor-
mation “is going to be publicly available and of
real interest and usefulness to both specialists
and general scientists.” A 754 VOLUME 110 | NUMBER 12 | December 2002 • Environmental Health Perspectives
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On “-Omics”— A Glossary 
Data mining: The extraction of relevant
parameters stored in a database.
Genomics: The study of genes and
their function. Genomics differs from
genetics in that genetics looks at
single genes, one at a time, whereas
genomics looks at all genes, over
time, to determine how they interact
and influence biological pathways,
networks, and physiology.
Metabolomics: The study of the total
metabolite pool (the metabolome)
through a wide spectrum of techno-
logic methods including liquid chro-
matography–mass spectrometry, gas
chromatography–mass spectrometry,
and nuclear magnetic resonance.
Microarray: Sets of miniaturized chem-
ical reaction areas that may also be
used to test DNA fragments, antibod-
ies, or proteins.
Proteomics: The study of the full set
of proteins (the proteome) encoded
by a genome.
Single nucleotide polymorphism (SNP):
A position in the genome where some
individuals have one DNA base (e.g.,
A) and others have a different base
(e.g.,C). SNPs and point mutations are
structurally identical, differing only in
their frequency. Variations that occur
in 1% or less of a population are con-
sidered point mutations, and those
occurring in more than 1% are consid-
ered SNPs.
Toxicogenomics: The study of how
genomes respond to environmental
stressors or toxicants. Combines ge-
nome-wide mRNA expression profil-
ing with protein expression patterns,
using bioinformatics to understand
the role of gene–environment inter-
actions in disease and dysfunction.
Transcriptomics: The generation of
messenger RNA expression profiles.
Metabonomics: The study of the total
metabolite pool (the metabolome)
specifically through nuclear magnetic
resonance profiling.
Bioinformatics: The science of man-
aging and analyzing biological data
using advanced computing techni-
ques. Especially important in analyz-
ing genomic research data.
Pharmacogenomics: The analysis of
the effect of genomics—in particular,
genetic variation (polymorphisms)—
on drug response.
Pharmacogenetics: A subset of phar-
macogenomics encompassing the
study of genetic variation underlying
differential response to drugs, partic-
ularly genes involved in drug metab-
olism. Often used to refer specifically
to tests that predict drug response.Environmental Health Perspectives • VOLUME 110 | NUMBER 12 | December 2002  A 755
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The ILSI committee has already complet-
ed the first phase of its research—profiling tox-
icogenomic parameters for chemicals with
hepatotoxic, nephrotoxic, and genotoxic
mechanisms. “The idea is to make the data
complementary with CEBS and available in [a
form that can be accessed by others],” Pennie
says. “The NCT will have continual access,
and I hope the data sharing will be reciprocal.”
According to Pennie, these data are also being
prepared for entry into a database managed by
the European Bioinformatics Institute, a
multinational research organization based in
England. 
The prospect of sharing data across data-
bases and research centers raises a highly chal-
lenging issue: the standardization of experi-
mental protocols and data formats. Therefore,
a system for ensuring uniform data quality is of
key importance, experts say. However, as in
any field, toxicogenomic experiments are high-
ly variable in terms of approach, outcome, and
interpretation. 
One line of reasoning suggests that scien-
tists should apply standardized methods to
minimize this variability. According to Pennie,
the ILSI committee tackled this question as
one of its first priorities. But after a period of
internal debate, he says, committee members
concluded that standardized approaches
wouldn’t yet be possible to adopt, in part
because they felt researchers shouldn’t be con-
strained in method development. “The tech-
niques are still evolving at a rapid pace,” he
explains. “Furthermore, we want to under-
stand what the sources of variability are.”
With respect to standardization, both
Pennie and Waters (whose NCT duties include
project officership of the CEBS database) say
they will lean heavily on the recommendations
of the Microarray Gene Expression Data
Society, an international organization working
to facilitate the sharing of microarray data. This
group has developed a core set of guidelines
that is loosely termed Minimum Information
About a Microarray Experiment, or MIAME.
According to the society’s website, these guide-
lines, which apply to microarray gene expres-
sion research, will “assist in the development of
microarray data repositories and data analysis
tools.” The guidelines provide a uniform
nomenclature for describing toxicogenomic
experiments and data. Says Waters, “With
regards to CEBS, we will follow the recom-
mendations coming from that society in addi-
tion to the guidance we obtain from the
Toxicogenomics Research Consortium and the
NIEHS Microarray Center.” 
Practical Applications
The implications of toxicogenomic re-
search ultimately extend far beyond labora-
tories and clinics, and reach into public
and environmental policy. Even now, policy
experts are grappling with fundamental
questions about how toxicogenomic data
will transform the process of setting stan-
dards for chemical hazards. The risk assess-
ment protocols used to set these standards
have always focused on protecting the most
sensitive subgroups of the human popula-
tion. Usually, these subgroups are defined
using equations that relate human responses
to lowest-observed-effect levels seen in ani-
mal experiments. These low-level effects—
usually fairly benign responses such as
altered lung function or changes in blood
chemistry—are thought to be shared by all
members of the population. Therefore, the
standards are said to protect against “popu-
lation-level effects.” 
Now, toxicogenomics is revising the con-
cept of low-level effects. Once the purview of
the pathologist, the limits of sensitivity are
increasingly being defined according to genet-
ic susceptibility to toxic exposure. Therefore,
sensitive subgroups are transformed from an
amorphous entity into a clearly defined genet-
ic subset of individuals within the population.
According to Richard Sharp, an assistant
professor of medical ethics at the Center for
Medical Ethics and Health Policy of the Baylor
College of Medicine, the identification of
these subpopulations raises some important
questions. Most importantly, who bears the
cost of protecting these individuals? This issue
will likely first come to bear in the workplace,
he says. Once sensitive subgroups are defined,
employers may deny jobs to applicants on the
basis of genetic screens that show them to be
sensitive to workplace hazards. “How much
discretion should an employer have to make
these kinds of decisions?” Sharp asks. Sharp
chairs an NCT working group on ethical,
legal, and policy issues that is now exploring
this and other issues.
Regulatory agencies are also grappling
with toxicogenomics issues. In June 2002, the
U.S. Environmental Protection Agency (EPA)
issued its first guidelines for using genomics
data for the standard-setting process. In the
guidelines, the agency opined that toxicoge-
nomics will potentially have an “enormous
impact on our ability to assess the risk from
exposure to stressors and ultimately to
improve our risk assessments.” But the guide-
lines also make clear that “the relationships
between changes in gene expression and
adverse effects are unclear at this time and
may be difficult to evaluate.” The EPA’s cur-
rent position on the matter is that, although
useful, toxicogenomic data alone are insuffi-
cient to characterize risk. Therefore, the
agency will accept the data but will consider
them only on a case-by-case basis. 
The U.S. Food and Drug Administration
(FDA) is also closely watching developments
in the field. Frank Sistare, director of the
Division of Applied Pharmacology Research
at the FDA’s Center for Drug Evaluation and
Research, says the administration has just
completed a series of multistakeholder meet-
ings on the use of genomic data for drug
evaluations. A report describing the FDA’s
position on the issue is now being prepared.
Echoing the concerns of EPA officials,
Sistare emphasizes the difficulty of linking
microarray results to adverse effects. With
respect to submitting toxicogenomic data for
drug approval processes, Sistare says, “It’s
more of a challenge to industry than it is to
us right now. I don’t think anyone can pro-
vide a clear answer on what every signal
means on an experiment conducted with
microarrays that query thousands of end
points at once. This puts industry in the
unenviable position of generating all these
data that they can’t really explain.”
If data are produced for safety evaluations,
they must be submitted to the FDA by law,
Sistare adds. Therefore, companies must
decide whether the studies are worth the
investment, particularly if the resultant data
simply immerses them in a drug approval
quagmire. Sistare admits the policy might
deter drug and biotechnology companies from
undertaking toxicogenomic research on devel-
opmental compounds. Referring to this partic-
ular issue, Sistare adds that viewpoints both
within and outside the FDA suggest that com-
panies pursuing toxicogenomic studies for new
drug screening (when potential drugs are
selected for further research and development)
should not be obligated to submit their exper-
imental data. “Either way,” he says, “we don’t
want to inhibit application of the technology
to drug development. We think it’s a powerful
tool, and all of us need to come to resolution
on when the data need to be submitted, how
the data should be submitted, and how we are
going to use them.”
Clearly, toxicogenomics is a new field
brimming with potential benefits. But many
challenges remain. Scientists are just beginning
to explore the remarkable complexities of cel-
lular response mechanisms. And assembling
the pieces of the toxicogenomics puzzle is a
challenge that will require ever more sophisti-
cated technology and decades of research. But
the environmental health payoff is significant:
more effective diagnosis and treatment of envi-
ronmentally related diseases, expedited evalua-
tions of chemicals and new drugs, and better
risk assessment. “We have to understand how
all the pathways fit together in a systems biol-
ogy perspective,” concludes Samson. “That’s
the biggest hurdle of all.” 
Charles W. Schmidt